GAD has an estimated lifetime prevalence of 7.8% and a 1-year prevalence of 4% in the US. In Europe, estimates for 1-month prevalence are approximately 0.2% to 1.5%, with a lifetime prevalence of around 1% to 7%. Around 4.0% to 7.9% of primary care patients and 22.0% of people presenting with anxiety are diagnosed with GAD.
BMJ Best Practice is an evidence-based point of care tool for healthcare practitioners.
To continue reading and access all of BMJ Best Practice's pages you'll need to log in or start a free trial.
You can access through your institution if your hospital, university, trust or other institution provides access to BMJ Best Practice through either OpenAthens or Shibboleth.
Use of this content is subject to our disclaimer